Dynamic ¹⁸F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts

References

• Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685–93.
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795–803.
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7:987–9.
   PubMed Web of Science ®Google Scholar
• Harper J, Moses M. Molecular regulation of tumor angiogenesis: Mechanisms and therapeutic implications. In: Bignold LP, editor. Cancer: Cell structures, carcinogens and genomic instability. Experientia Supplementum. Berlin: Birkhaauser Basel; 2006.
   Google Scholar
• Schneider BP, Sledge GW. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007;4:181–9.
   PubMedGoogle Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Disc 2004;3:391–8.
   PubMed Web of Science ®Google Scholar
• Cao C, Wang J, Bunjhoo H, Xu Y, Fang H. Risk profile of bevacizumab in patients with non-small cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncol 2012;51:151–6.
   PubMed Web of Science ®Google Scholar
• Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst 2005;97:172–87.
   PubMed Web of Science ®Google Scholar
• Drevs J, Schneider V. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. J Intern Med 2006;260:517–29.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956; 123:309–14.
   PubMed Web of Science ®Google Scholar
• Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis—compartmental model. Ann Nucl Med 2006;20:583–8.
   PubMed Web of Science ®Google Scholar
• Dunnwald LK Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: Value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res 2011;17: 2400–9.
   PubMed Web of Science ®Google Scholar
• Revheim ME, Kristian A, Malinen E, Bruland ØS, Berner JM, Holm R, et al. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol 2013; 52:776–82.
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009;3:469–82.
   PubMed Web of Science ®Google Scholar
• Qi J, Leahy RM. Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans Med Imaging 2000;19:493–506.
   PubMed Web of Science ®Google Scholar
• Røe K, Aleksandersen TB, Kristian A, Nilsen LB, Seierstad T, Qu H, et al. Preclinical dynamic 18F-FDG PET – tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol 2010;49:914–21.
   PubMed Web of Science ®Google Scholar
• Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, et al. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol Oncol 2012;6:418–27.
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012;21:82–91.
   PubMed Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13: 3942–50.
   PubMed Web of Science ®Google Scholar
• Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007;13: 3395–402.
   PubMed Web of Science ®Google Scholar
• Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PE. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9: 355–62.
   PubMed Web of Science ®Google Scholar
• Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L. Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: Noninvasive monitoring with functional MR imaging pilot study. Radiology 2003;228:63–9.
   PubMed Web of Science ®Google Scholar
• Li SP, Makris A, Beresford MJ, Taylor NJ, Ah-See ML, Stirling JJ, et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology 2011;260:68–78.
   PubMed Web of Science ®Google Scholar
• Lederle W, Palmowski M, Kiessling F. Imaging in the age of molecular medicine: Monitoring of anti-angiogenic treatments. Curr Pharm Biotechnol 2012;13:595–608.
   PubMed Web of Science ®Google Scholar
• Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic (18)FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol Epub 2012 Dec 3.
   PubMed Web of Science ®Google Scholar
• Malinen, E, Rødal J, Knudtsen IS, Søvik Å, Skogmo HK. Spatiotemporal analysis of tumor uptake patterns in dynamic (18)FDG-PET and dynamic contrast enhanced CT. Acta Oncol 2011;50:873–82.
   PubMed Web of Science ®Google Scholar
• Mullani NA, Herbst RS, O’Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 2008;49:517–23.
   PubMed Web of Science ®Google Scholar
• Eby PR, Partridge SC, White SW, Doot RK, Dunnwald LK, Schubert EK, et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. Acad Radiol 2008;15:1246–54.
   PubMed Web of Science ®Google Scholar